Geneart

In Brief This Week is a column containing news items that our readers may have missed during the week.

The firm, which now majority-owned by Life Technologies, also posted a sharp gain in its earnings before interest and taxes.

Life Tech now owns 74 percent of the synthetic gene company.

Life Technologies has made a tender offer to acquire the remaining shares of Geneart that it does not already own for around €25.5 million. The total purchase price was approximately €56 million.

The agreement gives Applied Biosystems Deutschland approximately 58 percent of GeneArt's shares.

A proposed HHS guidance for synthetic biology roughly fits a harmonization effort started by the International Gene Synthesis Consortium.

Five firms have formed the International Gene Synthesis Consortium to set gene and customer screening protocols that address security concerns.

The firm's sales increased despite the expiration of an NIH contract.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.